Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
2.820
-0.030 (-1.05%)
Apr 22, 2026, 10:50 AM EDT - Market open
Ovid Therapeutics Revenue
In the year 2025, Ovid Therapeutics had annual revenue of $7.25M with 1,181.27% growth. Ovid Therapeutics had revenue of $718.00K in the quarter ending December 31, 2025, with 844.74% growth.
Revenue (ttm)
$7.25M
Revenue Growth
+1,181.27%
P/S Ratio
51.83
Revenue / Employee
$315,304
Employees
23
Market Cap
371.89M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.25M | 6.69M | 1,181.27% |
| Dec 31, 2024 | 566.00K | 174.00K | 44.39% |
| Dec 31, 2023 | 392.00K | -1.11M | -73.91% |
| Dec 31, 2022 | 1.50M | -206.88M | -99.28% |
| Dec 31, 2021 | 208.38M | 195.77M | 1,551.58% |
| Dec 31, 2020 | 12.62M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 228.37M |
| Bicycle Therapeutics | 72.59M |
| Enanta Pharmaceuticals | 66.98M |
| X4 Pharmaceuticals | 35.11M |
| Opus Genetics | 14.20M |
| Surrozen | 3.48M |
| Silence Therapeutics | 559.00K |
| Avalo Therapeutics | 59.00K |
OVID News
- 14 days ago - Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14 - GlobeNewsWire
- 5 weeks ago - Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally - Benzinga
- 5 weeks ago - Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Ovid Therapeutics Announces Pricing of $60 Million Private Placement - GlobeNewsWire
- 2 months ago - Ovid Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) - GlobeNewsWire
- 5 months ago - Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer - GlobeNewsWire
- 5 months ago - Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results - GlobeNewsWire